NCT06474533 Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
| NCT ID | NCT06474533 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Hope |
| Condition | Intracranial Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 199 participants |
| Start Date | 2024-06-21 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 199 participants in total. It began in 2024-06-21 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Eligibility Criteria
Inclusion Criteria: * Presence or suspicion of intracranial neoplasm in two populations: * Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI. * Three sub-populations will be considered: * Recurrent metastatic lesions. * Recurrent high-grade gliomas (Grades 3 and 4). * Recurrent low-grade gliomas (Grade 2). * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection. * Age \> 3 years. Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid. Exclusion Criteria: * Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans. * Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation. * Sedation or anesthesia can be used for participants who cannot tolerate the exam.
Contact & Investigator
Javier Villanueva-Meyer, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06474533 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, studying Intracranial Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06474533 currently recruiting?
Yes, NCT06474533 is actively recruiting participants. Contact the research team at Louise.Magat@ucsf.edu for enrollment information.
Where is the NCT06474533 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06474533 clinical trial?
NCT06474533 is sponsored by Thomas Hope. The principal investigator is Javier Villanueva-Meyer, MD at University of California, San Francisco. The trial plans to enroll 199 participants.